	pSS patients (n=26)	Healthy controls (n=22)
Age, mean +/- SD (range) years	58 +/- 14	58+/- 19.13
Female sex (%)	100	100
No antibody (%)	7 (27)	100
anti-SSA+ anti SSB- (%)	8 (31)	
anti-SSA+ anti-SSB+ (%)	11 (42)	NA
ESSDAI, mean +/- SD (range)	3.5 +/- 4 (0 - 15)	NA
Treatments:		
Methotrexate (15mg/week) (%)	1 (3)	NA
Hydroxychloroquine (400mg/d)		
(%)	7 (27)	NA

Supplementary table S1: Characteristics of the analyzed cohort with primary Sjögren's syndrome (pSS) and healthy controls

Supplementary table S2. List of significantly differentially methylated IFN regulated genes (IRGs) found in B lymphocytes from seropositive and seronegative pSS patients (red denotes hypomethylated genes; green hypermethylated genes; blue are genes with both hyper- and hypomethylated probes). Genes with at least 2 CpG sites significantly differentially methylated (at least 7% median difference of methylation, p<0.01) were included in the analysis.

Differentially methylated IRGs found in anti-SSA+ anti-SSB + patients	Differentially methylated IRGs found in anti-SSA+ anti-SSB- patients	Differentially methylated IRGs found in anti-SSA - patients
76 genes	24 genes	2 genes
AHNAK	AMPD3	AR
AIM2	ARHGEF15	DHX58
AMPD3	ATP1B2	
ARAP1	CBFA2T3	
ARHGEF2	CDH18	
ARID5A	FOXO3	
ATXNI	HOXB2	
CBFA2T3	IFI44L	
CCL8	IFITM1	
CD80	IFITM3	
CETP	ISG15	
CHST15	JARID2	
CPM	KIAA0754	
DLG4	MACF1	

DTX3L	MAP3K5	
DUSP2	<i>N4BP3</i>	
EMP1	PARP12	
FAM49A	PHLDA2	
FAM53B	RABGAP1L	
FGL2	RPL3	
FOXO3	RSAD2	
GATM	SBNO2	
GNA12	SNRPN	
HMHA1	ZAP70	
HOXB2		
IFI44L		
IFITM1		
IFITM3		
IL10RA		
IRAK3		
IRF7		
ISG15		
ITPR2		
JARID2		
LAG3		
LGALS3BP		
LPCATI		
MXI		
N4BP3		
NF1		
PARP12		
PARP9		
PGM1		
PHACTR4		
PIK3CD		
PLSCR1		
PPFIBP2		
PPM1H		
PRDM2		
PRKCA		
PRKCE		
PTPRCAP		
RAB8B		
RADOD RASSF2		
RASSF2 RERE		
RPL13A		
RPL3		
RSAD2		
RUNX3		
SBNO2		

SECTM1		
SH2B2		
SLAMF7		
SNRPN		
SOCS1		
SOCS2		
SORL1		
SP140		
SPATS2L		
STK17A		
TG		
TNF		
TREM1		
TRIP6		
USP6NL		
ZMIZ1		